Iván Márquez-Rodas

21PUBLICATIONS

129CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyNanomedicineEpidemiological modellingPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (21)

Sort by Publication Date:

|Jul 07, 2026

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

|Jul 27, 2025

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801).

Pablo Ayala-de Miguel, Eva Muñoz-Couselo, Lourdes Gutiérrez-Sanz

|Jun 27, 2025

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag

|Nov 09, 2024

Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.

Michael Weichenthal, Joanna Mangana, Iva Gavrilova

|Nov 06, 2024

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Georgina V Long, James Larkin, Dirk Schadendorf

|Aug 05, 2024

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey Weber, Michele Del Vecchio, Mario Mandalá

Pageof 4

Frequent Collaborators

5 joint publications

Paolo Antonio Ascierto

Mario Mandala

Georgina V Long

James Larkin

Luis de la Cruz-Merino

Jean-Jacques Grob

Helen Gogas

Corey Ritchings

Vanna Chiarion-Sileni

3 joint publications

Jeffrey Weber

Frequent Collaborators

5 joint publications

Paolo Antonio Ascierto

4 joint publications

Mario Mandala

4 joint publications

Georgina V Long

4 joint publications

James Larkin